Hangzhou Diagens Biotechnology Co Ltd (Ticker: 2526 HK) is a China-domiciled medical device company specializing in the development of medical imaging products and services. The company’s primary focus is its core product, AI AutoVision, an auxiliary diagnostic software designed for intelligent chromosome karyotyping analysis used in prenatal diagnosis and assisted reproduction. Diagens plans to list its H shares on the Main Board of the Hong Kong Stock Exchange on March 30, 2026.

The company priced its IPO on March 27, 2026, offering 8.00 million shares at HKD 99.00 per share. The offering raised approximately HKD 792 million (equivalent to USD 101.09 million). At the offer price, the company’s market capitalization is reportedly USD 1.12 billion. According to the prospectus, Diagens intends to use the proceeds for research and development, enhancing production capacity, brand promotion, business development, working capital, and strategic acquisitions. The offering is sponsored by Huatai Financial Holdings, with a management group including ABCI Capital, BOCI Asia, and CCB International. The company's core technology has reportedly been recognized as a "Class III Innovative Medical Device" by the NMPA, allowing for an expedited regulatory path in China.